Published: Monday, June 16, 2025 · 1:45 AM | Updated: Monday, June 16, 2025 · 1:45 AM
📊 333 views
Innovent Biologics (IVBXF, Financial) has commenced the GLORY-OSA Phase 3 clinical trial, dosing its first participant. The trial focuses on mazdutide, a dual receptor agonist targeting glucagon and glucagon-like peptide-1, in Chinese patients suffering from moderate-to-severe obstructive sleep apnea and obesity. This marks the seventh Phase 3 study for mazdutide in China, emphasizing its potential role in treating obesity and related metabolic disorders. The goal is to acquire robust evidence to support clinical applications of this treatment.
MORE IN INSIDE INVESTMENT NEWS
Micron: A Bullish Outlook Driven by AI Demand
Published: Wednesday, September 30, 2026 · 9:07 PM
Costco’s Membership Momentum: A Bullish Signal for Portfolios
Published: Thursday, September 24, 2026 · 10:26 PM
